Alumis Inc (ALMS)vsRegeneron Pharmaceuticals Inc (REGN)
ALMS
Alumis Inc
$23.07
-1.24%
HEALTHCARE · Cap: $3.17B
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 59538% more annual revenue ($14.34B vs $24.05M). REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
ALMS
Avoid24
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALMS.
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Trading at 8.0x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMS
The strongest argument for ALMS centers on Debt/Equity.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : ALMS
The primary concerns for ALMS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 24/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alumis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alumis Inc. (ALMS) is an innovative leader in the development and commercialization of high-performance aluminum products, serving critical sectors such as automotive, aerospace, and construction. The company harnesses proprietary technologies to advance material science while adhering to sustainable manufacturing practices, ensuring minimal environmental impact. Focused on research and development, Alumis is strategically positioned to capitalize on emerging market opportunities and expand its diverse product portfolio. With a commitment to operational excellence and stakeholder value, Alumis aims to sustain long-term growth through continuous innovation.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?